Latest Ratios: P/E Ratio -8.4x · EV/EBITDA N/A · ROE N/A. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $23M | $86M | $145M | $33M | $20M | $90M | — |
| Enterprise Value | $25M | $88M | $146M | $36M | $23M | $90M | — |
| P/E Ratio → | -8.38 | — | — | — | — | 104.28 | — |
| P/S Ratio | 3.40 | 12.58 | 36.17 | 8.84 | 5.26 | 19.79 | — |
| P/B Ratio | — | — | — | — | — | 150.35 | — |
| P/FCF | — | — | — | — | — | 204.13 | — |
| P/OCF | — | — | — | — | — | 203.23 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.89 | 36.43 | 9.69 | 6.21 | 19.85 | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 84.13 | — |
| EV / FCF | — | — | — | — | — | 204.75 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 43.9% | 43.9% | 19.0% | 22.7% | 23.1% | 27.4% | 43.8% |
| Operating Margin | -35.8% | -35.8% | -432.2% | -106.9% | -151.9% | -12.3% | -10.1% |
| Net Profit Margin | -40.7% | -40.7% | -382.9% | -270.9% | -661.1% | 19.0% | 2.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | 611.8% | — |
| ROA | -160.9% | -160.9% | -1010.2% | -74.5% | -148.0% | 12.5% | 3.0% |
| ROIC | — | — | — | — | -913.9% | -82.8% | -472.5% |
| ROCE | — | — | — | — | — | -238.3% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.77 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | 0.45 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | 0.62 | — |
| Interest Coverage | -10.92 | -10.92 | -392.00 | -362.18 | -264.57 | 8.46 | -13.58 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.18 | 0.18 | 0.18 | 0.08 | 0.86 | 0.59 | 0.70 |
| Quick Ratio | 0.18 | 0.18 | 0.15 | 0.08 | 0.84 | 0.59 | 0.70 |
| Cash Ratio | 0.06 | 0.06 | 0.06 | 0.02 | 0.00 | 0.03 | 0.04 |
| Asset Turnover | — | 3.97 | 2.32 | 2.83 | 0.15 | 0.57 | 1.51 |
| Inventory Turnover | 1345.80 | 1345.80 | 25.19 | — | 4.47 | — | — |
| Days Sales Outstanding | — | 17.89 | 15.49 | 23.55 | 18.70 | 327.35 | 66.41 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 1.0% | — |
| FCF Yield | — | — | — | — | — | 0.5% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $2M | $2M | $1M | $601483 | $462667 | $371113 |
Imminent liquidity and dilution
Based on reported figures, EUDA's P/S ratio of 4.15 suggests the market is pricing the firm at a significant discount compared to broader digital health peers, likely reflecting the high risk of insolvency and the lack of a clear path to positive earnings in the near term.
The current valuation appears to be heavily influenced by the company's precarious cash position rather than its top-line growth potential. Investors should note that the forward P/E of 126.75 implies an optimistic recovery that may not be supported by the current negative operating margins.
As reported in financial statements, EUDA's gross margin of 27.3% in the most recent quarter indicates a structural limitation in its service-heavy model, which prevents the company from achieving the high-margin profile typically associated with pure-play software or platform-based healthcare information services.
The persistent negative net margin of -39.4% suggests that the company's operating expenses remain far too high relative to its current revenue scale. This indicates that the business model may be fundamentally challenged by the high costs of medical service delivery in the Singaporean market.
According to recent quarterly data, EUDA's cash conversion cycle has fluctuated significantly, with the most recent period showing a CCC of 9 days, which suggests that the company is struggling to maintain consistent control over its receivables and payables during its rapid expansion phase.
The volatility in DSO and DPO metrics warrants further investigation, as it may indicate inconsistent collection practices or reliance on supplier credit to manage liquidity. Such inefficiencies are particularly concerning given the company's extremely limited cash reserves and the need for precise working capital management.
Based on the most recent financial statements, EUDA's current ratio of 0.23 highlights a severe inability to cover short-term obligations, suggesting that the company's cash runway is likely exhausted and that it faces an acute risk of insolvency without immediate, likely dilutive, external capital injections.
The company's liquidity position is among the most vulnerable in its peer group, leaving little room for operational error or market volatility. Investors should monitor the balance sheet closely, as the current cash balance of $345,145 is insufficient to sustain the ongoing quarterly cash burn.
The most commonly misapplied metric for EUDA is the top-line revenue growth rate, which, while appearing robust at 70% YoY, obscures the fact that this growth is likely driven by low-margin, labor-intensive medical services rather than scalable, high-margin software licensing or data analytics platform fees.
Analysts should focus on the 'contribution margin' per member rather than gross revenue to better understand the true earning power of the business. Relying on revenue growth alone ignores the reality that the company's current cost structure is not scaling efficiently with its top-line expansion.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EUDA stock.
EUDA Health Holdings Limited's current P/E ratio is -8.4x. The historical average is 104.3x.
Based on historical data, EUDA Health Holdings Limited is trading at a P/E of -8.4x. Compare with industry peers and growth rates for a complete picture.
EUDA Health Holdings Limited has 43.9% gross margin and -35.8% operating margin.